Pettigrew Morgan F, Al Abbas Amr I, Southichack Anida, Ju Michelle R, Hammer Suntrea T G, Liu Yulun, Porembka Matthew R, Wang Sam C
Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.
Tissue Management Shared Resource, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.
J Surg Res. 2025 Feb;306:230-238. doi: 10.1016/j.jss.2024.12.002. Epub 2025 Jan 10.
Human tissue samples are essential for translational cancer research. However, less than 20% of current biobank and genomic samples were obtained from minority patients, which may lead to biased understanding of cancer biology. The objective of this study was to identify factors associated with patient enrollment in our institution's gastric cancer biobank.
Patients with suspected or confirmed gastric or gastroesophageal junction cancer undergoing surgical procedures at our institution were invited to enroll in a prospective gastric cancer biobank. We retrospectively reviewed patients who were invited to enroll from 2017 to 2023 at our safety-net and university hospitals. We compared patients who enrolled to those who declined to identify factors that predict enrollment.
Hispanic patients had similar odds of enrollment as non-Hispanic White patients (odds ratio (OR): 1.22, 95% confidence interval (CI): 0.54-2.73, P = 0.63). Non-Hispanic minorities (Black/African Americans and Asians) were less likely to enroll when compared to non-Hispanic Whites (OR: 0.41, 95% CI: 0.18-0.95, P = 0.04). Minority patients treated at our safety-net hospital had higher odds of enrollment than those treated at our university hospital (OR: 2.62, 95% CI: 1.11-5.99, P = 0.02).
Efforts to improve diversity in biomedical research cannot consider minority patients as a monolithic cohort. Instead, targeted interventions that address diverse cultural concerns and improve access to enrollment at safety-net centers are requisite.
人体组织样本对于转化性癌症研究至关重要。然而，目前生物样本库和基因组样本中，只有不到20%来自少数族裔患者，这可能导致对癌症生物学的理解存在偏差。本研究的目的是确定与我院胃癌生物样本库患者入组相关的因素。
在我院接受手术的疑似或确诊胃癌或胃食管交界癌患者被邀请加入一个前瞻性胃癌生物样本库。我们回顾性分析了2017年至2023年期间在我院安全网医院和大学医院被邀请入组的患者。我们比较了入组患者和拒绝入组患者，以确定预测入组的因素。
西班牙裔患者的入组几率与非西班牙裔白人患者相似（优势比（OR）：1.22，95%置信区间（CI）：0.54-2.73，P = 0.63）。与非西班牙裔白人相比，非西班牙裔少数族裔（黑人/非裔美国人和亚洲人）入组的可能性较小（OR：0.41，95% CI：0.18-0.95，P = 0.04）。在我院安全网医院接受治疗的少数族裔患者入组几率高于在大学医院接受治疗的患者（OR：2.62，95% CI：1.11-5.99，P = 0.02）。
改善生物医学研究多样性的努力不能将少数族裔患者视为一个单一的群体。相反，需要有针对性的干预措施，解决各种文化问题，并改善在安全网中心的入组机会。
